ReviewNature reviews. Nephrology2019
Antimicrobial resistance in nephrology.
Review in Nature reviews. Nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 75 citations in OpenAlex.
- Evaluation of high dose post-dialytic versus daily beta-lactam dosing in hemodialysis patients using Monte Carlo simulation.International journal of clinical pharmacy · 2026Article
- Prescribing Patterns and Clinical Outcomes of Ceftolozane/Tazobactam by Renal Function and Body Mass Index: A SPECTRA Real-World Multi-Country Analysis.Antibiotics (Basel, Switzerland) · 2026Article
- Draft genomes of four multidrug-resistant (MDR) Gammaproteobacteria from biofilm on hemodialysis catheters in Gujarat, India.Microbiology resource announcements · 2026Article
- Feeding the invaders: how metabolic imbalance shapes infection and biofilm development.FEMS microbiology reviews · 2026Review
- Inflammation, infection, and immune dysregulation in chronic kidney disease: translational and epidemiological perspectives.Frontiers in nephrology · 2026Review
- Reported practices and difficulties for preventing emerging highly resistant bacteria in hemodialysis: the PHYDEL survey.GMS hygiene and infection control · 2026Article
- The association between empirical antibiotic regimens and the outcome of peritoneal dialysis-related peritonitis: a multi-center, large-scale cohort study.Journal of nephrology · 2025Article
- Article
- Unravelling the Antibiotic Resistance: Molecular Insights and Combating Therapies.Applied biochemistry and biotechnology · 2025Review
- Observational
- Resistance Profiles and Virulence Factors of EntericInternational journal of microbiology · 2025Article
- Current and emerging strategies to curb antibiotic-resistant urinary tract infections.Nature reviews. Urology · 2024Review
- Protecting healthcare and patient pathways from infection and antimicrobial resistance.BMJ (Clinical research ed.) · 2024Article
- Incidence of Cytomegalovirus Infection After Repeat Keratoplasty and Associated Rate of Graft Failure.Ophthalmology and therapy · 2024Article
- Practical Lessons on Antimicrobial Therapy for Critically Ill Patients.Antibiotics (Basel, Switzerland) · 2024Review
- Effects of Vancomycin Subtherapeutic Concentration on Staphylococcus aureus Isolated from Hemodialysis Patients with Low Serum Trough Concentrations.Current microbiology · 2024Article
- Uropathogen and host responses in pyelonephritis.Nature reviews. Nephrology · 2023Review
- Analyses of Extended-Spectrum-β-Lactamase, Metallo-β-Lactamase, and AmpC-β-Lactamase Producing Enterobacteriaceae from the Dairy Value Chain in India.Antibiotics (Basel, Switzerland) · 2023Article
- Safety and Tolerability of Antimicrobial Agents in the Older Patient.Drugs & aging · 2023Review
- Socioecological factors linked with pharmaceutical incentive-driven prescribing in Pakistan.BMJ global health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The prevalence of antimicrobial resistance among many common bacterial pathogens is increasing. The emergence and global dissemination of these antibiotic-resistant bacteria (ARB) is fuelled by antibiotic selection pressure, inter-organism transmission of resistance determinants, suboptimal infection prevention practices and increasing ease and frequency of international travel, among other factors. Patients with chronic kidney disease, particularly those with end-stage renal disease who require dialysis and/or kidney transplantation, have some of the highest rates of colonization and infection with ARB worldwide. These ARB include methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus spp. and several multidrug-resistant Gram-negative organisms. Antimicrobial resistance limits treatment options and increases the risk of infection-related morbidity and mortality. Several new antibiotic agents with activity against some of the most common ARB have been developed, but resistance to these agents is already emerging and highlights the dire need for new treatment options as well as consistent implementation and improvement of basic infection prevention practices. Clinicians involved in the care of patients with renal disease must be familiar with the local epidemiology of ARB, remain vigilant for the emergence of novel resistance patterns and adhere strictly to practices proven to prevent transmission of ARB and other pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.